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Abstract 
 
The starfish SALMFamide neuropeptides S1 (GFNSALMFamide) and S2 (SGPYSFNSGLTFamide) 
are the prototypical members of a family of neuropeptides that act as muscle relaxants in echinoderms. 
Comparison of the bioactivity of S1 and S2 as muscle relaxants has revealed that S2 is ten times more 
potent than S1. Here we investigated a structural basis for this difference in potency by comparing the 
bioactivity and solution conformations (using NMR and CD spectroscopy) of S1 and S2 with three 
chimeric analogs of these peptides. A peptide comprising S1 with the addition of S2‟s N-terminal 
tetrapeptide (Long S1 or LS1; SGPYGFNSALMFamide) was not significantly different to S1 in its 
bioactivity and did not exhibit concentration-dependent structuring seen with S2. An analog of S1 with 
its penultimate residue substituted from S2 (S1(T); GFNSALTFamide) exhibited S1-like bioactivity 
and structure. However, an analog of S2 with its penultimate residue substituted from S1 (S2(M); 
SGPYSFNSGLMFamide) exhibited loss of S2-type bioactivity and structural properties. Collectively, 
our data indicate that the C-terminal regions of S1 and S2 are the key determinants of their differing 
bioactivity. However, the N-terminal region of S2 may influence its bioactivity by conferring structural 
stability in solution. Thus, analysis of chimeric SALMFamides has revealed how neuropeptide 
bioactivity is determined by a complex interplay of sequence and conformation.      
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1. Introduction 
 The SALMFamides are a family of neuropeptides that occur in species belonging to the phylum 
Echinodermata (e.g. starfish, sea cucumbers, sea urchins). There are two types of SALMFamides – L-
type, which have the C-terminal motif SxLxFamide (where x is variable), and F-type, which have the 
C-terminal motif SxFxFamide. Furthermore, analysis of the pharmacological actions of SALMFamides 
has revealed that both L-type and F-type SALMFamides cause muscle relaxation in echinoderms [1, 2]. 
 The first members of the SALMFamide neuropeptide family to be identified were the L-type 
SALMFamides S1 and S2, which were both isolated from the nervous system of the starfish species 
Asterias rubens and Asterias forbesi [3]. S1 is an octapeptide with the amino acid sequence H-Gly-Phe-
Asn-Ser-Ala-Leu-Met-Phe-NH2 and S2 is a dodecapeptide with the amino acid sequence H-Ser-Gly-
Pro-Tyr-Ser-Phe-Asn-Ser-Gly-Leu-Thr-Phe-NH2 (Fig. 1). Interestingly, injection of S1 or S2 into A. 
rubens triggers cardiac stomach eversion, a process that occurs naturally when starfish feed extra-orally 
on prey such as mussels [4]. Consistent with the effects of S1 and S2 in vivo, both peptides cause dose-
dependent relaxation of cardiac stomach preparations in vitro [4, 5]. Furthermore, S1-immunoreactive 
and S2-immunoreactive nerve fibres are present in the innervation of the cardiac stomach, in close 
proximity to the muscle layer [6]. Therefore, it is thought that endogenous release of S1 and/or S2 may 
be responsible, at least in part, for mediating cardiac stomach eversion when starfish feed.  
 Comparison of the potency of S1 and S2 as cardiac stomach relaxants in vitro has revealed that 
S2 is approximately ten times more potent than S1 [2, 4, 7]. Similarly, when tested at the same 
concentration on other muscle preparations from A. rubens (tube feet and apical muscle) the relaxing 
effect of S2 is consistently greater than the effect of S1 [7, 8]. This difference in the potency/activity of 
S1 and S2 provided a basis for comparative analysis of the solution structures of S1 and S2 using 
circular dichroism (CD) spectroscopy and nuclear magnetic resonance (NMR) spectroscopy [7]. 
Consistent with previous studies on small neuropeptides [9-12], CD and NMR data indicate that S1 
does not have defined conformation in aqueous solution. In contrast, it was found that S2 has a 
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remarkably well-defined conformation in aqueous solution, with more than 220 NOEs identified in 
NMR NOESY data. However, the structuring of S2 is concentration dependent, with increasing 
concentration inducing a transition from an unstructured to a structured conformation. This indicates 
that at high concentrations oligomers of S2 are formed through self-association [7] whilst at 
physiological concentrations S2 remains unstructured. 
 The most striking difference in the sequences of S1 and S2 is the presence of the N-terminal 
SGPY tetrapeptide in S2 that is lacking in S1 (Fig. 1). Therefore, it was hypothesized that the N-
terminal region of S2 may facilitate self-association of the S2 peptide at high concentrations. 
Consistent with this hypothesis, it was found that an N-terminally truncated analog of S2 lacking the 
SGPY tetrapeptide sequence (short S2 or SS2; SFNSGLTFamide) does not have a defined structure in 
aqueous solution [7]. However, comparative analysis of the bioactivity of S2 and SS2 yielded 
conflicting findings. S2 was more effective than SS2 as a muscle relaxant when tested at 1 µM and 10 
µM on cardiac stomach preparations and when tested at 1 µM on tube foot preparations. However, SS2 
was more effective as a muscle relaxant than S2 when tested on tube feet at 10 µM [7]. It is not clear, 
therefore, to what extent the presence of the N-terminal SGPY tetrapeptide and its effect in facilitating 
peptide self-association are important for the bioactivity of S2. Additional studies are now needed to 
further investigate the structure-activity relationships of S1 and S2.  
 Here we have analysed the solution structures and bioactivity of three novel chimeric analogs of 
S1 and S2. Firstly, Long S1 (LS1; SGPYGFNSALMFamide) is a dodecapeptide comprising S1 with 
the addition of the N-terminal four residues of S2 (SGPY). Analysis of this peptide enabled further 
investigation of the contribution of the N-terminal SGPY tetrapeptide in facilitating peptide self-
association and for bioactivity.  Secondly, S1(T), in which the penultimate residue of S1 (methionine) 
is replaced by the residue that occupies this position in S2 (threonine). Thirdly, S2(M), in which the 
penultimate residue of S2 (threonine) is replaced by the residue that occupies this position in S1 
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(methionine). Analysis of S1(T) and S2(M) enabled assessment of the contribution of C-terminal amino 
acid residues for SALMFamide structure and activity. 
  
 6 
2. Materials and Methods 
 
2.1 Materials 
 Peptides were custom-synthesized by the Advanced Biotechnology Centre at Imperial College 
London and purified using high performance liquid chromatography. All other chemicals used were 
obtained from VWR (Poole, Dorset, UK) with the exception of D2O, which was obtained from Goss 
Scientific Instruments Ltd (Great Baddow, Essex, UK). 
 
2.2 In vitro pharmacology 
 S1 and S2 cause dose-dependent relaxation of cardiac stomach and tube foot preparations from 
the starfish A. rubens. Therefore, these preparations were used here to assess the bioactivity of three 
chimeric analogs of S1 and S2 (LS1, S1(T) and S2(M)), employing the same methodology as reported 
previously [4, 7, 8]. Specimens of A. rubens were obtained from the Menai Straits (UK) and maintained 
in a circulating seawater aquarium in the School of Biological & Chemical Sciences at QMUL. Cardiac 
stomach and tube foot preparations were dissected, set up in organ baths containing seawater at 11qC 
and their contractility was measured using isotonic transducers (model 60-3001; Harvard, South 
Natick, MA, USA) linked to a chart recorder (Goerz Servogor 124). To enable assessment of the 
bioactivity of the chimeric peptides as muscle relaxants, sustained contracture of preparations was 
induced and maintained using seawater with 30 mM added KCl, as described previously [4, 7, 8]. 
LS1, S1(T) and S2(M) were tested on cardiac stomach preparations (n = 4, 8 and 3, 
respectively) and tube foot preparations (n = 9, 6 and 6, respectively) at three concentrations, 0.1 µM, 
1.0 µM and 10µM, and the effects of the peptides were expressed as a percentage of the relaxing effect 
of 10 µM S2, which was ascribed a value of 100%. To directly compare the bioactivity of the chimeric 
peptides with both S1 and S2, experiments were performed where S1, S2 and a chimeric peptide (LS1, 
S1(T) or S2(M)) were tested at a concentration of 1 µM on cardiac stomach preparations (n = 12, 7 and 
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10, respectively) and tube foot preparations (n = 13, 12 and 13, respectively). In these experiments, 
each peptide was tested twice and the order in which peptides were tested was randomised, with effects 
quantified by normalisation to the effect of 1 µM S2.   
 
2.3 Circular dichroism (CD) spectroscopy 
 CD spectra were recorded using a Chirascan CD spectrometer (Applied Photophysics Ltd.) 
equipped with a Peltier temperature controller. Spectra were the average of three scans recorded with a 
1 nm bandwidth, a 0.5 nm step size, and a 5 s time constant. After background subtraction, the 
observed ellipticity (T; mdeg) was converted to a molar ellipticity ('(; M-1 cm-1), using the formula: 
'( = T/(33000 lc) where l is the path length (cm) and c is the concentration (M). To examine the effect 
of temperature, CD spectra were obtained every 5qC from 10 to 90q using a 1 mm path length for a 0.1 
mg/ml samples and a 1 cm path length for  a 0.01 mg/ml samples. 
 
2.4 NMR spectroscopy 
 Peptides were dissolved in 10% D2O/90% H2O to achieve a final concentration of 2 mM. The 
pH of the solutions was adjusted to pH 5.6 using 10 mM NaOH and 10 mM HCl. The peptide solutions 
were centrifuged to remove any suspended material and then the supernatant was transferred to 5 mm 
NMR tubes. Data were acquired using a Bruker Avance 600 MHz spectrometer and collected using 
Topspin software on a UNIX workstation. All experiments were performed using a 5 mm TXI, triple 
resonance probe equipped with a z-axis gradient. 2D NMR spectra were obtained at 303 K for LS1 and 
283K for S1(T) and S2(M). Water suppression was achieved using a Water Gradient Tailored 
Excitation (WATERGATE) technique. 2D-Total Correlation Spectroscopy (TOCSY) experiments 
employed a DIPSI2 sequence for isotropic mixing, with a 65 ms mixing time. A 300 ms mixing time 
was used for Nuclear Overhauser Effect Spectroscopy (NOESY) and Rotating-frame Overhauser Effect 
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SpectroscopY (ROESY) experiments.  All 2D experiments used STATES-TPPI phase cycling, and a 
spectral width of 14 ppm was applied in both dimensions with 2048 x 512 complex data points in the t2 
and t1 dimensions, respectively. Prior to Fourier Transformation (FT), the data were linear predicted in 
the F1 dimension to 512 real points and then zero filled to produce a final matrix size of 4k x 1k, with a 
90o phase-shifted sine squared window function applied to both dimensions. The chemical shifts were 
referenced to water at 4.7 ppm at 303K, pH 5.6. Spin-systems were manually assigned using the 
TOCSY data and sequential assignments were completed using the 300 ms NOESY or ROESY spectra. 
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3. Results 
 
3.1 In vitro pharmacology 
 
3.1.1 LongS1 (LS1) 
 An N-terminally extended analog of S1 (SGPYGFNSALMFamide or LS1) with the addition of 
the N-terminal tetrapeptide sequence (SGPY) from S2 was synthesized to investigate if addition of the 
N-terminal region would confer on S1 bioactivity comparable to that of S2. LS1 was tested on cardiac 
stomach and tube foot preparations at concentrations ranging from 0.1 PM to 10 PM, with the effect at 
each concentration expressed as a percentage of the effect of 10 PM S2. LS1 caused dose-dependent 
relaxation of cardiac stomach preparations, with 0.1 PM LS1 causing 38 r 10% relaxation and 1 PM 
causing 67 r 8% relaxation. At 10 PM, the effect of LS1 (69 rwas not significantly different to 
the effect of 1 PM LS1 (p = 0.74; t-test) (Fig. 2A). LS1 also caused dose-dependent relaxation of tube 
foot preparations. However, compared to the effects of LS1 on cardiac stomach, LS1 was less effective 
in causing relaxation of tube feet, with 14 r 5% relaxation at 0.1 PM, 20 r 4 % relaxation at 1 PM and 
37r 8% relaxation (Fig. 2C).  
 To compare the bioactivity of LS1 with S1 and S2, the effects of all three peptides on cardiac 
stomach (Fig. 2B) and tube foot (Fig. 2D) preparations were compared at a concentration of 1 PM, 
expressed as a percentage of the effect of 1 µM S2. The mean effect of LS1 on cardiac stomach 
preparations at 1 PM (70 r 5% relaxation) was significantly less than the mean effect of 1 PM S2 (p= 
4.65 E-06; t-test), but was not significantly different to the mean effect of 1 PM S1 (p = 0.138; t-test). 
The mean effect of LS1 on tube foot preparations at 1 PM (21r 5% relaxation) was significantly less 
than the mean effect of 1 PM S2 (p = 9.04 E-10; t-test) but was not significantly different to the mean 
effect of 1 PM S1 (p = 0.14; t-test).  
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 Collectively, these data indicate that addition of the SGPY tetrapeptide sequence to the N-
terminus of S1 does not confer on S1 bioactivity equivalent to that of S2. Furthermore, because the 
efficacy of LS1 as a muscle relaxant was found not to be significantly different to that of S1, 
differences in the potency/efficacy of S1 and S2 appear to be largely determined by differences in their 
C-terminal regions. To test this hypothesis, C-terminal analogs of S1 and S2 were synthesized and 
tested.   
 
3.1.2 S1(T) 
An analog of S1, GFNSALTFamide or S1(T), was synthesized wherein the residue in S1 that is 
penultimate to the C-terminal amide (methionine) was replaced with the residue that is in an equivalent 
position in S2 (threonine). S1(T) caused dose-dependent relaxation of cardiac stomach preparations, 
with 0.1 PM causing 30 r 6% relaxation, 1 PM producing 52 r 7% relaxation and 10 PM producing 95 
r 5% relaxation, in comparison with 10 PM S2 (Fig. 2E). S1(T) also caused dose-dependent relaxation 
of tube foot preparations, with 0.1 PM S1(T) causing 1 r 0.2% relaxation, 1 PM S1(T) causing 10 r 
3% relaxation and 10 PM produced 83 r 16% relaxation, in comparison with 10 PM S2 (Fig. 2G).  
Comparison of the effects of S1(T), S1 and S2 on cardiac stomach preparations at 1 PM 
revealed that the effect of S1(T) at 1 PM (68r 8% relaxation) was significantly less than the effect of 1 
PM S2 (p = 0.006; t-test) and was not significantly different to the effect of 1 PM S1 (p = 0.4; t-test) 
(Fig. 2F). Comparison of the effects of S1(T), S1 and S2 on tube foot preparations at 1 PM revealed 
that the effect of S1(T) at 1 PM (21r 3% relaxation) was significantly less than the effect of 1 PM S2 
(p = 7.856E-11; t-test) but was not significantly different to the effect of S1 at 1 PM (p = 0.1; t-test) 
(Fig. 2H). 
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Thus, collectively the results of the experiments with S1(T) indicate that substitution of the C-
terminal methionine residue in S1 with the equivalently positioned residue in S2 is not sufficient to 
confer on S1 the potency/efficacy of S2. 
 
3.1.3 S2(M) 
 An analog of S2, SGPYSFNSGLMFamide or S2(M), was synthesized wherein the residue in S2 
that is penultimate to the C-terminal amide (threonine) was replaced with the residue that is in an 
equivalent position in S1 (methionine). S2(M) caused dose-dependent relaxation of cardiac stomach 
preparations, with 0.1 PM S2(M) causing 18 r 8% relaxation, 1 PM S2(M) causing 43 r 6% relaxation 
and 10 PM causing 99 r 10% relaxation, in comparison with the effect of 10 PM S2 (Fig. 2I). S2(M) 
also caused dose-dependent relaxation of tube foot preparations, with 0.1 PM S2(M) causing 5 ± 4% 
relaxation, 1 PM causing 15 ± 4% relaxation and 10 PM causing 40 ± 10% relaxation, in comparison 
with the effect of 10 PM S2 (Fig. 2K). 
 Comparison of the effects of S2(M), S1 and S2 at 1 PM on cardiac stomach preparations 
revealed that the effect of S2(M) was significantly less than the effect of 1 PM S2 (47 ± 5% relaxation; 
p = 1.648E-8;t-test) but not significantly different to the effect of 1 PM S1 (p = 0.012; t-test) (Fig. 2J). 
Likewise, comparison of the effect of S2(M), S1 and S2 at 1 PM on tube foot preparations revealed that 
the effect of S2(M) was significantly less than the effect of S2 (13 ± 3% relaxation; p = 8.999E-12; t-
test) but not significantly different to the effect of S1 at 1 PM (p = 0.241; t-test) (Fig. 2L). 
Collectively, these data indicate the C-terminally located threonine residue in S2 contributes to 
its superior potency/efficacy in comparison with S1 because substitution of this residue with the 
equivalently positioned residue from S1 (methionine) leads to a loss of bioactivity such that the effects 
of the S2 analog S2(M) are not significantly different to the effects of S1.  
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3.2 Structural analysis of LS1, S1(T) and S2(M) using NMR 
3.2.1 Long S1 (LS1) 
 Previously we determined that loss of the four N-terminal amino acids from S2 resulted in a 
loss of concentration dependent structuring and loss of bioactivity [7]. However, addition of SGPY to 
the N-terminus of S1 does not confer S2-like bioactivity (Fig. 2). Therefore, removal of the N-terminal 
tetrapeptide from S2 (short S2 or SS2) results in loss of structure, but addition of the SGPY motif to S1 
may not be sufficient to generate structure. To investigate this we obtained two-dimensional TOCSY 
and NOESY NMR spectra of LS1. From the 2D TOCSY we were able to assign all residues except 
Ser1. When the ROESY spectrum of S1 (Fig. 3A) is compared to that of LS1 (Fig. 3B) it is clear that 
LS1 has far more NOE peaks than S1. The greater number of NOEs in LS1 (Fig. 3B) suggests that the 
addition of four N-terminal amino acids has resulted in the generation of some structure in LS1. 
However, the presence of substantial structure would result in a number of long-range NOE contacts. 
Inspection of the HN-HD region of the overlaid LS1 TOCSY and NOESY spectra shows that there are 
mostly only sequential connections apparent (Fig. 3C). Only one medium range NOE, a dDN(i, i+2), is 
apparent between Leu10 and Phe12, however this may be an ambiguous assignment and will be 
discussed later. Also observed is a d1N(i, i+2) between Ala9 and Leu11 as well as sequential dNN(i, i+1) 
connections between Gly5 and Phe6 and Leu11 and Phe12 (not shown). This suggests that most of the 
apparent structure is located in the C-terminal region. This result is in contrast to S2, in which many 
medium and long range NOEs covering the entire peptide were apparent in the HN-HD region [7]. 
Overall, in the LS1 NOESY spectrum we were able to identify 77 NOEs compared to the more than 
220 NOEs observed in S2 [7]. Thus, the N-terminal tetrapeptide can induce some conformational 
preference, but the structure is not as extensive as observed in S2 and in itself is not sufficient to 
promote S2-like bioactivity.  
 
 13 
3.2.2 S1(T)  
 S1(T) contains a threonine residue in the penultimate position, as in S2, instead of the 
methionine residue present in S1. Other than the four N-terminal residues, S1 differs from S2 only at 
this position and at position five (S1 numbering) which is a glycine in S2 and an alanine in S1. We 
hypothesised that the threonine for methionine substitution may result in increased potency/efficacy but  
the pharmacological tests showed that bioactivity of S1(T) was not significantly different to S1 (Fig. 2E 
– H). Analysis of the NMR data supports this finding. The ROESY spectrum of S1(T) (Fig. 4A) is 
similar to that of S1 (Fig. 4B). The chemical shifts are all near their „random coil‟ values and there are 
no ROEs present beyond sequential connectivities, indicating that S1(T), like S1, is largely 
unstructured. If the penultimate threonine is indeed important in receptor binding, perhaps by being 
involved in hydrogen-bonding via the side-chain hydroxyl group, then it must require the structuring 
induced by the N-terminal tetrapeptide in S2 in order to be placed in the correct position.          
     
3.2.3 S2(M) 
 If Thr11 is important for S2 bioactivity, then S2(M), which contains the penultimate methionine 
from S1 instead of Thr11, should have reduced bioactivity. The pharmacology results have supported 
this, showing that S2(M) is no more effective than S1 as a muscle relaxant (Fig. 2I-L).  Comparison of 
the HN-HD region of the ROESY spectrum of S2(M) (Fig. 5A) with the same region of S2 (Fig. 5B) 
shows that S2(M) also lacks the array of ROEs indicative of structure that are abundant in S2.  Likely, 
a loss of structure has resulted in the lack of ROEs. Indeed, the number of ROEs in S2(M) is similar to 
LS1 as might be expected given that S2(M) and LS1 differ only by one amino acid at position 9 – 
alanine in LS1 and glycine in S2(M). Closer inspection of the HN-HD region of the overlaid TOCSY 
and ROESY spectra in Fig. 5C shows that S2(M) adopts multiple conformations. All long peptides (S2, 
LS1, S2(M)) that contain Pro3 have cis and trans conformations due to the proline, however S2(M) also 
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has an additional two conformations around Met11. Figure 5C shows that the sequential HN-HD 
connections can follow two divergent paths from Gly9 and consequently Leu10, Met11 and Phe12 have 
two distinct chemical shifts. This suggests that S2(M) can adopt at least four distinct conformations – 
Pro3TransMet11a, Pro3TransMet11b; Pro3CisMet11a and Pro3CisMet11b. Possibly, the splitting of the C-terminal 
residues is a consequence of the cis/trans Pro3 isomerism and could suggest association of the N-
terminal region with the C-terminus either within a folded monomer or possibly in a „head-to-tail‟ 
dimer. However, it is notable that the cis-Proline is a minor component while the signals for the two 
sets of Met11 have similar intensities. If the two conformations of Leu10, Met11 and Phe12 were a result 
of the Pro3 cis/trans isomerisation then it could reasonably be expected that the peak intensities would 
mimic the Pro3 intensities, i.e. one set would have markedly reduced intensity. It is likely then that the 
splitting of Leu10 – Phe12 residues is not related to the cis/trans Pro3 isomerism. The ambiguity in the 
assignment of the dDN(i, i+2) connection between Leu10 and Phe12 in LS1 is because there may also be 
some minor doubling of the Met11 peak in LS1, however any chemical shift difference is minor and the 
TOCSY does not provide sufficient evidence for a second peak. The clear presence of multiple 
conformations in the C-terminal region of S2(M) would undoubtedly impact on the ability of the 
peptide to bind to receptors and induce muscle relaxation. Taken together, the pharmacology and 
structural data indicate that the combination of the four N-terminal residues along with the presence of 
threonine in the penultimate position is necessary to form a peptide with optimal bioactivity. Possibly, 
the side-chain hydroxyl is required for hydrogen bonding with the S2 receptor.  
 
3.3 Structural analysis of LS1 and S2(M) using CD spectroscopy 
 The number of ROEs observed in the ROESY spectra of LS1 and S2(M) (Fig. 3, 5) has 
suggested that both these peptides contain some structure. Previous studies have shown that structure in 
S2 was a consequence of self-association [7], and therefore we now wondered if LS1 and S2(M) also 
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exhibit S2-like concentration-dependent structuring. CD is a useful technique for the determination of 
protein and peptide structure. In the UV region of the CD spectrum the presence of stable structure 
results in optical activity due to the chirality around the amide bond. Initially, we obtained CD spectra 
of LS1 and S2(M) at low concentrations similar to those used in the pharmacology experiments and 
higher concentrations similar to the concentrations used in the NMR experiments (Fig. 6). For LS1 
(Fig. 6A) the CD spectra obtained at both concentrations are very similar. At the lower concentration 
(0.011 mg/mL) the presence of a strong negative peak near 200 nm along with a positive peak at 225 
nm suggests the presence of polyproline-II (PP-II) character [13]. PP-II is a highly extended 
conformation that does not contain backbone hydrogen bonds and is frequently found in „unstructured‟ 
regions of proteins. At a ten-fold higher concentration, the UV CD spectrum of LS1 is similar to that at 
the lower concentration, the negative peak at 200 nm has got stronger (i.e. more negative) but a small 
peak at 225 nm is retained. This suggests that a similar structure is adopted at both concentrations.  
 The CD spectra of S2(M) at high and low concentrations (Fig. 6B) are very different to LS1 
(Fig. 6A) and to S2 [7].  The spectra have a positive peak at 207 nm and negative peaks at 215 nm and 
225 nm. In the higher concentration spectrum the peak at 215 nm that is readily apparent at the lower 
concentration appears as a shoulder on the more intense 225 nm peak.  The S2(M) spectra are quite 
novel and don‟t resemble the spectra that would be obtained from any regular secondary structural 
element nor an unstructured peptide, which would feature a single negative band at a198 nm. 
Furthermore, the lack of similarity to LS1 suggests that S2(M) also does not adopt a PPII conformation. 
Given that the NMR data suggest that S2(M) can adopt at least four different conformations, the CD 
spectrum at the higher concentration is likely a summation of all of these different conformations. The 
fact that the CD spectrum of the lower concentration does not resemble the spectrum of an unstructured 
peptide indicates that, in contrast to S2, S2(M) retains some structure at the concentrations used in the 
pharmacology experiments.    
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 To further investigate the structure of LS1 and S2(M) we undertook temperature dependent 
unfolding experiments. As the temperature is increased from 10qC to 90qC the CD spectra of LS1 
shows a loss of the positive band at 225 nm at both low (Fig. 7A) and high (Fig. 7B) concentrations. 
These data suggest that the PPII structure is lost at higher temperatures; it is notable that even at 90qC, 
and at both concentrations, a negative CD band is observed at 230 nm suggesting some self-
association. As expected, the loss of PPII structure is not cooperative unfolding at either concentration 
(Fig. 7C, D).  The rather unusual CD spectra of S2(M) are very different to those of LS1 -  at the higher 
concentration (Fig. 8A) the negative CD signal at 225 nm remains almost unaffected by raising the 
temperature to 70qC, while there is a significant loss of positive signal at 207 nm. At the lower S2(M) 
concentration (Fig. 8B) the signal loss at 207 nm is more marked, accompanied by a negative band at 
217 nm even at 70qC, which suggests an extended conformation due to self-association.  It is notable 
that at 70qC with both concentrations of S2(M) the spectra do not show evidence for a completely 
unfolded peptide. The thermal denaturation curves (Fig. 8C, D) suggest a sharp transition in structure at 
50qC with a marked loss of the positive CD band at 207 nm. 
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4. Discussion 
 
 The SALMFamide neuropeptides S1 and S2, which share 67% sequence 
identity (Fig. 1), act as muscle relaxants in starfish, but S2 is about ten times more potent than S1. In a 
previous study [7] a structural basis for this difference in the potency of S1 and S2 was investigated, 
focusing on the N-terminal SGPY tetrapeptide that is a feature of the S2 dodecapeptide 
(SGPYSFNSGLTFamide) but not the S1 octapeptide (GFNSALMFamide). It was found that the N-
terminal SGPY motif confers on S2 the property of self-association induced structure at high 
concentrations. Given that S2 structuring is only apparent at high concentrations it is most likely not 
relevant to the physiological roles of S2 as a muscle relaxant in starfish. We note, though, that recent 
studies with bradykinin peptides have shown that conformation can be quite dependent on solution 
composition and it remains possible that other conditions will modify S2‟s oligomerization and 
conformation [14]. We have proposed that the ability of S2 to oligomerize may have implications for 
peptide packing in vesicles prior to release and possibly also for autocrine actions of the peptide 
directly after release when local concentrations are high. Analysis of the bioactivity of an N-terminally 
truncated form of S2 (SS2; SFNSGLTFamide), which like S1 does not exhibit self-association induced 
structure, yielded ambiguous findings - the bioactivity of SS2 was found to be either inferior or 
superior to that of S2, depending on the dose and muscle preparation tested. Thus, the contribution of 
the N-terminal SGPY sequence to the bioactivity of S2 remains unclear. Here we have further 
investigated this issue by analysis of the bioactivity and structural properties of chimeric analogs of S1 
and S2. 
 Long S1 or LS1 (SGPYGFNSALMFamide), a chimeric peptide comprising the N-terminal 
tetrapeptide of S2 and the C-terminal octapeptide of S1, was tested and analysed to investigate if 
addition of the N-terminal SGPY sequence would confer S2-like bioactivity and structure on S1. It was 
found that the bioactivity of LS1 as a muscle relaxant was not significantly different to that of S1 and 
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that LS1 does not exhibit self-association induced structure.  However, some structuring was detected 
in the C-terminal region of LS1 and the presence of a positive peak at 225 nm in CD spectra suggests 
the presence of a polyproline-II-type conformation. Thus, addition of the N-terminal SGPY motif does 
confer some structure on S1, but it is not equivalent to that seen with S2 and does not appear to 
enhance bioactivity. Collectively, these findings indicate that the superior bioactivity of S2 in 
comparison with S1 is not largely attributable to the presence of the N-terminal SGPY motif in S2. 
Therefore, we investigated the contribution of residues that differ in the C-terminal region of S1 and 
S2. 
 The bioactivity of S1(T), an analog of S1 with a threonine residue replacing the methionine 
residue that is penultimate to the C-terminal amide in S1, was found not to be significantly different to 
that of S1. Furthermore, like S1 [7], the S1(T) octapeptide did not exhibit a stable structure in solution. 
Thus, conversion of the C-terminal region of S1 (LMFamide) to an S2-type C-terminal sequence 
(LTFamide) is not sufficient on its own to confer S2-like bioactivity on S1. However, conversion of the 
C-terminal region of S2 (LTFamide) to an S1-type C-terminal sequence (LMFamide) results in loss of 
S2-type bioactivity – thus, the relaxing effects of the S2 analog S2(M) are significantly less than the 
effects of S2 and not significantly different to the effects of S1. Interestingly, this amino acid 
conversion also results in loss of the self-associating property of S2 to form a stable conformation at 
high concentrations. However, like the LS1 peptide, S2(M) does exhibit some structuring but it lacks 
the stability seen with S2 at high concentrations and appears to adopt multiple conformations.  
 Collectively, the findings of our previous study [7] and the findings from the experiments 
reported here indicate that the superior bioactivity of S2 compared to S1 is largely attributable to 
differences in the C-terminal region of these peptides. In particular, the loss of bioactivity seen in the 
S2 analog S2(M) indicates that the C-terminal LTFamide motif of S2 appears to be a key determinant 
of its superior bioactivity in comparison with S1. This presumably reflects differences in the properties 
of threonine and methionine and hence how they may interact with residues that form receptor binding 
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sites for S2 - perhaps the side-chain hydroxyl group in the threonine residue is required for formation 
of hydrogen bonds. The presence of multiple conformations around Met11 in S2(M) suggests that, in 
addition to Thr11 potentially supporting interactions with the S2 receptor, it is also possible that this 
residue supports intra- or inter-molecular hydrogen-bonding. However, the contribution of the N-
terminal SGPY sequence to the bioactivity of S2 should not be dismissed. The reduced bioactivity of 
the N-terminally truncated form of S2 (SS2) seen in some preparations [7] indicates that the SGPY 
motif contributes to S2‟s bioactivity. The SGPY motif clearly confers varying degrees of structural 
stability on the dodecapeptides S2, LS1 and S2(M) and we propose that it is this property in 
combination with the C-terminal residues of S2 that accounts for S2‟s superior bioactivity in 
comparison with S1.  Further understanding of S2‟s bioactivity might be achieved if we could solve the 
structure of the high-concentration multimeric structure. However, solving the structure of monomeric 
S2 based on our NOESY data is very difficult because at NMR concentrations S2 is multimeric and 
lowering the concentration results in loss of structure. Under NMR conditions deconvoluting our NOE 
data to determine intra-monomer from inter-monomer contacts is not possible, especially for a peptide 
of only 12 amino-acids. Furthermore, it is difficult to assess how the multimeric structure has 
influenced NOE intensities and thus conversion of peak intensity to distant restraints is likely to result 
in incorrect distances. For example, a „head-to-head‟ dimer could result in NOE contacts for the same 
proton pair that is a mixture of both intra- and inter-residue contacts. Diffusion Ordered Spectroscopy 
of S2 was undertaken to try to elucidate the arrangement of the oligomeric structure (data not shown), 
but given the small size of the peptide it is very difficult to deconvolute the diffusion coefficient to 
differentiate an unfolded monomer from a folded dimer, trimer or tetramer.  
 In conclusion, our analysis of chimeric SALMFamide neuropeptides has revealed how 
neuropeptide bioactivity is determined by a complex interplay of sequence and conformation. Further 
insights into the structural basis of the differences in the potency of S1 and S2 as muscle relaxants in 
starfish could be obtained if the receptor(s) that mediate the effects of these peptides is/are identified. 
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Based on sequence similarities that SALMFamide-type neuropeptides share with neuropeptides that 
have been identified in other phyla, candidate G-protein coupled receptors for SALMFamides have 
been proposed (e.g. GnIH/NPFF-type and QRFP-type receptors; [1, 15]). However, definitive insights 
will require cloning, heterologous expression and pharmacological characterisation of candidate 
receptors. 
 Another fascinating avenue for future research will be to extend our analysis of the bioactivity 
and structural properties of S1, S2 and their chimeric analogs to other SALMFamide-type 
neuropeptides that have been discovered in starfish and in other echinoderms. Analysis of the genome 
sequence of the starfish Patiria miniata has revealed that S1 is derived from a precursor protein that 
contains six other L-type SALMFamides. On the other hand, the S2-like neuropeptide in P. miniata 
(SNGPYSMSGLRSLTFamide) is derived from a different precursor protein, which also comprises 
eight F-type or F-type-like SALMFamides [16]. Recently, sequencing of the neural transcriptome of A. 
rubens has enabled identification of corresponding precursors in this species, with S1 derived from a 
precursor comprising six L-type SALMFamides and S2 derived from a precursor comprising seven F-
type or F-type-like SALMFamides (D.C. Semmens & M.R. Elphick, unpublished data). 
Immunocytochemical localisation of S1 and S2 in A. rubens has revealed that these two peptides, and 
hence their precursor-associated peptides, are expressed in different populations of neurons [6, 17]. 
Therefore, we can collectively infer from these observations that S1 is released from neurons as one 
constituent of a “cocktail” of seven L-type SALMFamides. On the other hand, it appears that S2 is 
released by a different population of neurons as one constituent of a “cocktail” of eight SALMFamides, 
with the seven other peptides being F-type or F-type-like SALMFamides. Therefore, in comparing the 
bioactivity and structural properties of S1 and S2, as reported previously [7] and here, we are in fact 
comparing two L-type SALMFamides that are derived from different precursors and different 
populations of neurons. Furthermore, because both S1 and S2 are derived from precursor proteins that 
contain other SALMFamides, testing and comparing the effects of S1 and S2 in vitro is not 
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representative of a physiological scenario. In future studies it will be of interest to compare the 
structural and functional properties of S1 with other L-type SALMFamides that are derived from the S1 
precursor. Furthermore, analysis of the in vitro actions of a “cocktail” of the SALMFamides that are 
derived from the S1 precursor will reveal pharmacological actions that are representative of 
physiological processes in vivo. Similarly, it will be interesting to compare the effects of S2 with the 
effects of F-type and F-type-like SALMFamides that are derived from the S2 precursor and to compare 
the effects of peptides tested individually with the effects of the entire “cocktail” of SALMFamides that 
are derived from the S2 precursor. Combined with comparative analysis of the structural properties of 
all fifteen SALMFamides that are derived from the S1 and S2 precursors, it may then be possible to 
gain insights into the evolutionary and functional significance of the heterogeneous mixtures of 
SALMFamides that occur in starfish and in other echinoderms.  
 Our work on SALMFamides has broad relevance because the occurrence of multiple related 
neuropeptides derived from a single precursor protein is a common phenomenon, particularly in 
invertebrates [18]. However, the functional significance of these neuropeptide “cocktails” is not 
understood [19]. As an example, in the nematode C. elegans, a single precursor protein generates eight 
similar peptides belonging to the FMRFamide family of neuropeptides.  Deletion of this gene results in 
five distinct and different behavioural defects but it is not clear how individual peptides contribute to a 
specific phenotype [20]. Similar to our findings in this work, it appears that conformation preferences 
of individual FMRFamide-type neuropeptides in molluscs play a role in modulating receptor binding. It 
is suggested that only a single conformation will bind to the receptor and therefore the effective 
neuropeptide concentration is less than the expressed concentration [21]. Thus, an understanding of the 
interplay of sequence, conformation and intra- and inter-peptide interactions may be the key to 
elucidation of the functional significance of neuropeptide “cocktails”. 
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Figure Legends 
 
Figure 1. Comparison of the sequences of S1, S2,  SS2 (short S2), LS1 (long S1), S1(T) and S2(M). 
Residues that are identical in all six peptides are shown in black and residues that are variable or are 
not present in some peptides are shown in red. 
 
Figure 2. Analysis of pharmacological effects of LS1, S1(T) and S2(M) on cardiac stomach and tube 
foot preparations. A. LS1 causes dose-dependent relaxation of cardiac stomach preparations. However, 
although the effect 1 µM LS1 is significantly greater than 0.1 µM LS1 (p = 0.02; t-test), the effect of 1 
µM LS1 is not significantly different to the effect of 10 µM LS1 (p = 0.74; t-test). B. When tested at 1 
µM, LS1 is significantly less effective than S2 (p = 4.65E-06; ***; t-test) but is not significantly 
different to S1 (p = 0.138; t-test) as a relaxant of cardiac stomach preparations. C. LS1 causes dose-
dependent relaxation of tube foot preparations. D. When tested at 1 µM, LS1 is significantly less 
effective than S2 (p = 9.04E-10; ***; t-test) but is not significantly different to S1 (p = 0.14; t-test) as a 
relaxant of tube foot preparations. E. S1(T) causes dose-dependent relaxation of cardiac stomach 
preparations. F. When tested at 1 µM, S1(T) is significantly less effective than S2 (p = 0.0055; ***; t-
test) but is not significantly different to S1 (p = 0.4; t-test) as a relaxant of cardiac stomach 
preparations. G. S1(T) causes dose-dependent relaxation of tube foot preparations. H. When tested at 1 
µM, S1(T) is significantly less effective than S2 (p = 7.856 E-11; ***; t-test) but is not significantly 
different to S1 (p = 0.129; t-test) as a relaxant of the tube foot preparations. I. S2(M) causes dose-
dependent relaxation of cardiac stomach preparations. J. When tested at 1 µM, S2(M) is significantly 
less effective than S2 (p = 1.648E8; ***; t-test) but is not significantly different to S1 (p = 0.012; t-test) 
as a relaxant of cardiac stomach preparations K. S2(M) causes dose-dependent relaxation of tube foot 
preparations. L. When tested at 1 µM, S2(M) is significantly less effective than S2 (p = 8.999E-12; 
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***; t-test) but is not significantly different to S1 (p = 0.241; t-test) as a relaxant of the tube foot 
preparations. 
 
Figure 3.  Analysis by NMR (600 MHz) suggests LS1 contains some structure. The amide region of the 
ROESY spectrum (Wm = 300 ms) of S1 (A) shows no non-sequential cross-peaks which correlates with 
the lack of structure in this peptide. In contrast, the NOESY spectrum (Wm = 300 ms) of LS1 (B)  (2mM, 
pH 5.6, 303K) shows non-sequential cross-peaks, especially to the side-chains of Phe6/Phe12 between 
7.0 and 7.5 ppm, suggesting that LS1 contains some structure. Overlay of the NH-HD region of the LS1 
ROESY spectrum (red) and the TOCSY spectrum (Wm= 65 ms, blue) shows the sequential connections 
(solid lines) along with a possible dDN(i, i+2) connection between L10 and F12 (dotted line). 
 
Figure 4. S1T is not structured. The HN-HD region of 600 MHz ROESY spectrum (Wm = 300 ms) of 
S1(T) (2 mM, pH 5.6, 283K) (A) shows only sequential connectivities similarly to S1 (B) and both 
have a lack of medium and long range contacts that would indicate structure. The box labelled G1 
represents the intraresidue HN-HD peak of G1 observed in the TOCSY but not in the ROESY. 
 
Figure 5. S2(M) contains multiple conformations. The amide region of the 600 MHz NOESY spectrum 
(Wm = 300 ms) of S2(M) (2 mM, pH 5.4, 283K) (A) compared to the same region of the NOESY 
spectrum of S2 (B)  (C) Overlay of the NH-HD region of the S2(M) NOESY spectrum (red) and 
TOCSY spectrum (blue) shows sequential connections (solid lines). The dashed line highlights a 
second set of sequential connections from Leu10 to Phe12 that suggests the presence of an alternative 
conformation. 
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Figure 6. CD of LS1 and S2(M) at high and low concentrations. Panel A shows the CD spectra of LS1 
at low (0.011 mg/mL, black trace) and high (0.13 mg/mL, red trace) concentrations. The positive peak 
at 225 nm, particularly at low concentration, suggests the presence of polyproline II conformation. The 
CD spectra of S2(M) (Panel B) at low (0.012 mg/mL, black trace) and high (0.18 mg/mL red trace) are 
quite unusual and not typical of regular secondary structure. The presence of the positive band at 207 
nm and the negative band at 225 nm in both spectra suggests that the peptide has some similarity at 
both concentrations.      
 
Figure 7. Thermal melting CD spectra of LS1. Panel A shows the CD spectra of LS1 (0.13 mg/mL) 
obtained as the temperature is raised from 10qC (black trace) to 90qC (purple trace) in 5qC increments. 
Panel B shows the CD spectra of LS1 (0.011 mg/mL) obtained as the temperature is raised from 10qC 
(black trace) to 90qC (purple trace). In both cases a spectrum was obtained at 10qC after cooling from 
90qC and the unfolding was reversible. In neither high (Panel A) nor low concentration (Panel B) 
spectra is there evidence of a completely unfolded peptide, even at 90qC. Panels C and D show the 
ellipticity at 223 nm plotted as a function of temperature, and in neither case is there evidence of 
cooperative unfolding.    
 
Figure 8. Thermal melting CD spectra of S2(M). Panel A shows the CD spectra of S2(M) (0.18 
mg/mL) obtained as the temperature is raised from 10qC (black trace) to 70qC (blue trace) in 5qC 
increments. Panel B shows the CD spectra of S2(M) (0.012 mg/mL) obtained as the temperature is 
raised from 10qC (black trace) to 70qC (purple trace). In neither high (Panel A) nor low concentration 
(Panel B) spectra is there evidence of a completely unfolded peptide at the highest temperature tested. 
Panels C and D show the ellipticity at 207 nm, 217 nm and 225 nm plotted as a function of 
temperature. 
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Abstract 
 
The starfish SALMFamide neuropeptides S1 (GFNSALMFamide) and S2 (SGPYSFNSGLTFamide) 
are the prototypical members of a family of neuropeptides that act as muscle relaxants in echinoderms. 
Comparison of the bioactivity of S1 and S2 as muscle relaxants has revealed that S2 is ten times more 
potent than S1. Here we investigated a structural basis for this difference in potency by comparing the 
bioactivity and solution conformations (using NMR and CD spectroscopy) of S1 and S2 with three 
chimeric analogs of these peptides. A peptide comprising S1 with the addition of S2‟s N-terminal 
tetrapeptide (Long S1 or LS1; SGPYGFNSALMFamide) was not significantly different to S1 in its 
bioactivity and did not exhibit concentration-dependent structuring seen with S2. An analog of S1 with 
its penultimate residue substituted from S2 (S1(T); GFNSALTFamide) exhibited S1-like bioactivity 
and structure. However, an analog of S2 with its penultimate residue substituted from S1 (S2(M); 
SGPYSFNSGLMFamide) exhibited loss of S2-type bioactivity and structural properties. Collectively, 
our data indicate that the C-terminal regions of S1 and S2 are the key determinants of their differing 
bioactivity. However, the N-terminal region of S2 may influence its bioactivity by conferring structural 
stability in solution. Thus, analysis of chimeric SALMFamides has revealed how neuropeptide 
bioactivity is determined by a complex interplay of sequence and conformation.      
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1. Introduction 
 The SALMFamides are a family of neuropeptides that occur in species belonging to the phylum 
Echinodermata (e.g. starfish, sea cucumbers, sea urchins). There are two types of SALMFamides – L-
type, which have the C-terminal motif SxLxFamide (where x is variable), and F-type, which have the 
C-terminal motif SxFxFamide. Furthermore, analysis of the pharmacological actions of SALMFamides 
has revealed that both L-type and F-type SALMFamides cause muscle relaxation in echinoderms [1, 2]. 
 The first members of the SALMFamide neuropeptide family to be identified were the L-type 
SALMFamides S1 and S2, which were both isolated from the nervous system of the starfish species 
Asterias rubens and Asterias forbesi [3]. S1 is an octapeptide with the amino acid sequence H-Gly-Phe-
Asn-Ser-Ala-Leu-Met-Phe-NH2 and S2 is a dodecapeptide with the amino acid sequence H-Ser-Gly-
Pro-Tyr-Ser-Phe-Asn-Ser-Gly-Leu-Thr-Phe-NH2 (Fig. 1). Interestingly, injection of S1 or S2 into A. 
rubens triggers cardiac stomach eversion, a process that occurs naturally when starfish feed extra-orally 
on prey such as mussels [4]. Consistent with the effects of S1 and S2 in vivo, both peptides cause dose-
dependent relaxation of cardiac stomach preparations in vitro [4, 5]. Furthermore, S1-immunoreactive 
and S2-immunoreactive nerve fibres are present in the innervation of the cardiac stomach, in close 
proximity to the muscle layer [6]. Therefore, it is thought that endogenous release of S1 and/or S2 may 
be responsible, at least in part, for mediating cardiac stomach eversion when starfish feed.  
 Comparison of the potency of S1 and S2 as cardiac stomach relaxants in vitro has revealed that 
S2 is approximately ten times more potent than S1 [2, 4, 7]. Similarly, when tested at the same 
concentration on other muscle preparations from A. rubens (tube feet and apical muscle) the relaxing 
effect of S2 is consistently greater than the effect of S1 [7, 8]. This difference in the potency/activity of 
S1 and S2 provided a basis for comparative analysis of the solution structures of S1 and S2 using 
circular dichroism (CD) spectroscopy and nuclear magnetic resonance (NMR) spectroscopy [7]. 
Consistent with previous studies on small neuropeptides [9-12], CD and NMR data indicate that S1 
does not have defined conformation in aqueous solution. In contrast, it was found that S2 has a 
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remarkably well-defined conformation in aqueous solution, with more than 220 NOEs identified in 
NMR NOESY data. However, the structuring of S2 is concentration dependent, with increasing 
concentration inducing a transition from an unstructured to a structured conformation. This indicates 
that at high concentrations oligomers of S2 are formed through self-association [7] whilst at 
physiological concentrations S2 remains unstructured. 
 The most striking difference in the sequences of S1 and S2 is the presence of the N-terminal 
SGPY tetrapeptide in S2 that is lacking in S1 (Fig. 1). Therefore, it was hypothesized that the N-
terminal region of S2 may facilitate self-association of the S2 peptide at high concentrations. 
Consistent with this hypothesis, it was found that an N-terminally truncated analog of S2 lacking the 
SGPY tetrapeptide sequence (short S2 or SS2; SFNSGLTFamide) does not have a defined structure in 
aqueous solution [7]. However, comparative analysis of the bioactivity of S2 and SS2 yielded 
conflicting findings. S2 was more effective than SS2 as a muscle relaxant when tested at 1 µM and 10 
µM on cardiac stomach preparations and when tested at 1 µM on tube foot preparations. However, SS2 
was more effective as a muscle relaxant than S2 when tested on tube feet at 10 µM [7]. It is not clear, 
therefore, to what extent the presence of the N-terminal SGPY tetrapeptide and its effect in facilitating 
peptide self-association are important for the bioactivity of S2. Additional studies are now needed to 
further investigate the structure-activity relationships of S1 and S2.  
 Here we have analysed the solution structures and bioactivity of three novel chimeric analogs of 
S1 and S2. Firstly, Long S1 (LS1; SGPYGFNSALMFamide) is a dodecapeptide comprising S1 with 
the addition of the N-terminal four residues of S2 (SGPY). Analysis of this peptide enabled further 
investigation of the contribution of the N-terminal SGPY tetrapeptide in facilitating peptide self-
association and for bioactivity.  Secondly, S1(T), in which the penultimate residue of S1 (methionine) 
is replaced by the residue that occupies this position in S2 (threonine). Thirdly, S2(M), in which the 
penultimate residue of S2 (threonine) is replaced by the residue that occupies this position in S1 
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(methionine). Analysis of S1(T) and S2(M) enabled assessment of the contribution of C-terminal amino 
acid residues for SALMFamide structure and activity. 
  
 6 
2. Materials and Methods 
 
2.1 Materials 
 Peptides were custom-synthesized by the Advanced Biotechnology Centre at Imperial College 
London and purified using high performance liquid chromatography. All other chemicals used were 
obtained from VWR (Poole, Dorset, UK) with the exception of D2O, which was obtained from Goss 
Scientific Instruments Ltd (Great Baddow, Essex, UK). 
 
2.2 In vitro pharmacology 
 S1 and S2 cause dose-dependent relaxation of cardiac stomach and tube foot preparations from 
the starfish A. rubens. Therefore, these preparations were used here to assess the bioactivity of three 
chimeric analogs of S1 and S2 (LS1, S1(T) and S2(M)), employing the same methodology as reported 
previously [4, 7, 8]. Specimens of A. rubens were obtained from the Menai Straits (UK) and maintained 
in a circulating seawater aquarium in the School of Biological & Chemical Sciences at QMUL. Cardiac 
stomach and tube foot preparations were dissected, set up in organ baths containing seawater at 11qC 
and their contractility was measured using isotonic transducers (model 60-3001; Harvard, South 
Natick, MA, USA) linked to a chart recorder (Goerz Servogor 124). To enable assessment of the 
bioactivity of the chimeric peptides as muscle relaxants, sustained contracture of preparations was 
induced and maintained using seawater with 30 mM added KCl, as described previously [4, 7, 8]. 
LS1, S1(T) and S2(M) were tested on cardiac stomach preparations (n = 4, 8 and 3, 
respectively) and tube foot preparations (n = 9, 6 and 6, respectively) at three concentrations, 0.1 µM, 
1.0 µM and 10µM, and the effects of the peptides were expressed as a percentage of the relaxing effect 
of 10 µM S2, which was ascribed a value of 100%. To directly compare the bioactivity of the chimeric 
peptides with both S1 and S2, experiments were performed where S1, S2 and a chimeric peptide (LS1, 
S1(T) or S2(M)) were tested at a concentration of 1 µM on cardiac stomach preparations (n = 12, 7 and 
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10, respectively) and tube foot preparations (n = 13, 12 and 13, respectively). In these experiments, 
each peptide was tested twice and the order in which peptides were tested was randomised, with effects 
quantified by normalisation to the effect of 1 µM S2.   
 
2.3 Circular dichroism (CD) spectroscopy 
 CD spectra were recorded using a Chirascan CD spectrometer (Applied Photophysics Ltd.) 
equipped with a Peltier temperature controller. Spectra were the average of three scans recorded with a 
1 nm bandwidth, a 0.5 nm step size, and a 5 s time constant. After background subtraction, the 
observed ellipticity (T; mdeg) was converted to a molar ellipticity ('(; M-1 cm-1), using the formula: 
'( = T/(33000 lc) where l is the path length (cm) and c is the concentration (M). To examine the effect 
of temperature, CD spectra were obtained every 5qC from 10 to 90q using a 1 mm path length for a 0.1 
mg/ml samples and a 1 cm path length for  a 0.01 mg/ml samples. 
 
2.4 NMR spectroscopy 
 Peptides were dissolved in 10% D2O/90% H2O to achieve a final concentration of 2 mM. The 
pH of the solutions was adjusted to pH 5.6 using 10 mM NaOH and 10 mM HCl. The peptide solutions 
were centrifuged to remove any suspended material and then the supernatant was transferred to 5 mm 
NMR tubes. Data were acquired using a Bruker Avance 600 MHz spectrometer and collected using 
Topspin software on a UNIX workstation. All experiments were performed using a 5 mm TXI, triple 
resonance probe equipped with a z-axis gradient. 2D NMR spectra were obtained at 303 K for LS1 and 
283K for S1(T) and S2(M). Water suppression was achieved using a Water Gradient Tailored 
Excitation (WATERGATE) technique. 2D-Total Correlation Spectroscopy (TOCSY) experiments 
employed a DIPSI2 sequence for isotropic mixing, with a 65 ms mixing time. A 300 ms mixing time 
was used for Nuclear Overhauser Effect Spectroscopy (NOESY) and Rotating-frame Overhauser Effect 
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SpectroscopY (ROESY) experiments.  All 2D experiments used STATES-TPPI phase cycling, and a 
spectral width of 14 ppm was applied in both dimensions with 2048 x 512 complex data points in the t2 
and t1 dimensions, respectively. Prior to Fourier Transformation (FT), the data were linear predicted in 
the F1 dimension to 512 real points and then zero filled to produce a final matrix size of 4k x 1k, with a 
90o phase-shifted sine squared window function applied to both dimensions. The chemical shifts were 
referenced to water at 4.7 ppm at 303K, pH 5.6. Spin-systems were manually assigned using the 
TOCSY data and sequential assignments were completed using the 300 ms NOESY or ROESY spectra. 
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3. Results 
 
3.1 In vitro pharmacology 
 
3.1.1 LongS1 (LS1) 
 An N-terminally extended analog of S1 (SGPYGFNSALMFamide or LS1) with the addition of 
the N-terminal tetrapeptide sequence (SGPY) from S2 was synthesized to investigate if addition of the 
N-terminal region would confer on S1 bioactivity comparable to that of S2. LS1 was tested on cardiac 
stomach and tube foot preparations at concentrations ranging from 0.1 PM to 10 PM, with the effect at 
each concentration expressed as a percentage of the effect of 10 PM S2. LS1 caused dose-dependent 
relaxation of cardiac stomach preparations, with 0.1 PM LS1 causing 38 r 10% relaxation and 1 PM 
causing 67 r 8% relaxation. At 10 PM, the effect of LS1 (69 rwas not significantly different to 
the effect of 1 PM LS1 (p = 0.74; t-test) (Fig. 2A). LS1 also caused dose-dependent relaxation of tube 
foot preparations. However, compared to the effects of LS1 on cardiac stomach, LS1 was less effective 
in causing relaxation of tube feet, with 14 r 5% relaxation at 0.1 PM, 20 r 4 % relaxation at 1 PM and 
37r 8% relaxation (Fig. 2C).  
 To compare the bioactivity of LS1 with S1 and S2, the effects of all three peptides on cardiac 
stomach (Fig. 2B) and tube foot (Fig. 2D) preparations were compared at a concentration of 1 PM, 
expressed as a percentage of the effect of 1 µM S2. The mean effect of LS1 on cardiac stomach 
preparations at 1 PM (70 r 5% relaxation) was significantly less than the mean effect of 1 PM S2 (p= 
4.65 E-06; t-test), but was not significantly different to the mean effect of 1 PM S1 (p = 0.138; t-test). 
The mean effect of LS1 on tube foot preparations at 1 PM (21r 5% relaxation) was significantly less 
than the mean effect of 1 PM S2 (p = 9.04 E-10; t-test) but was not significantly different to the mean 
effect of 1 PM S1 (p = 0.14; t-test).  
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 Collectively, these data indicate that addition of the SGPY tetrapeptide sequence to the N-
terminus of S1 does not confer on S1 bioactivity equivalent to that of S2. Furthermore, because the 
efficacy of LS1 as a muscle relaxant was found not to be significantly different to that of S1, 
differences in the potency/efficacy of S1 and S2 appear to be largely determined by differences in their 
C-terminal regions. To test this hypothesis, C-terminal analogs of S1 and S2 were synthesized and 
tested.   
 
3.1.2 S1(T) 
An analog of S1, GFNSALTFamide or S1(T), was synthesized wherein the residue in S1 that is 
penultimate to the C-terminal amide (methionine) was replaced with the residue that is in an equivalent 
position in S2 (threonine). S1(T) caused dose-dependent relaxation of cardiac stomach preparations, 
with 0.1 PM causing 30 r 6% relaxation, 1 PM producing 52 r 7% relaxation and 10 PM producing 95 
r 5% relaxation, in comparison with 10 PM S2 (Fig. 2E). S1(T) also caused dose-dependent relaxation 
of tube foot preparations, with 0.1 PM S1(T) causing 1 r 0.2% relaxation, 1 PM S1(T) causing 10 r 
3% relaxation and 10 PM produced 83 r 16% relaxation, in comparison with 10 PM S2 (Fig. 2G).  
Comparison of the effects of S1(T), S1 and S2 on cardiac stomach preparations at 1 PM 
revealed that the effect of S1(T) at 1 PM (68r 8% relaxation) was significantly less than the effect of 1 
PM S2 (p = 0.006; t-test) and was not significantly different to the effect of 1 PM S1 (p = 0.4; t-test) 
(Fig. 2F). Comparison of the effects of S1(T), S1 and S2 on tube foot preparations at 1 PM revealed 
that the effect of S1(T) at 1 PM (21r 3% relaxation) was significantly less than the effect of 1 PM S2 
(p = 7.856E-11; t-test) but was not significantly different to the effect of S1 at 1 PM (p = 0.1; t-test) 
(Fig. 2H). 
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Thus, collectively the results of the experiments with S1(T) indicate that substitution of the C-
terminal methionine residue in S1 with the equivalently positioned residue in S2 is not sufficient to 
confer on S1 the potency/efficacy of S2. 
 
3.1.3 S2(M) 
 An analog of S2, SGPYSFNSGLMFamide or S2(M), was synthesized wherein the residue in S2 
that is penultimate to the C-terminal amide (threonine) was replaced with the residue that is in an 
equivalent position in S1 (methionine). S2(M) caused dose-dependent relaxation of cardiac stomach 
preparations, with 0.1 PM S2(M) causing 18 r 8% relaxation, 1 PM S2(M) causing 43 r 6% relaxation 
and 10 PM causing 99 r 10% relaxation, in comparison with the effect of 10 PM S2 (Fig. 2I). S2(M) 
also caused dose-dependent relaxation of tube foot preparations, with 0.1 PM S2(M) causing 5 ± 4% 
relaxation, 1 PM causing 15 ± 4% relaxation and 10 PM causing 40 ± 10% relaxation, in comparison 
with the effect of 10 PM S2 (Fig. 2K). 
 Comparison of the effects of S2(M), S1 and S2 at 1 PM on cardiac stomach preparations 
revealed that the effect of S2(M) was significantly less than the effect of 1 PM S2 (47 ± 5% relaxation; 
p = 1.648E-8;t-test) but not significantly different to the effect of 1 PM S1 (p = 0.012; t-test) (Fig. 2J). 
Likewise, comparison of the effect of S2(M), S1 and S2 at 1 PM on tube foot preparations revealed that 
the effect of S2(M) was significantly less than the effect of S2 (13 ± 3% relaxation; p = 8.999E-12; t-
test) but not significantly different to the effect of S1 at 1 PM (p = 0.241; t-test) (Fig. 2L). 
Collectively, these data indicate the C-terminally located threonine residue in S2 contributes to 
its superior potency/efficacy in comparison with S1 because substitution of this residue with the 
equivalently positioned residue from S1 (methionine) leads to a loss of bioactivity such that the effects 
of the S2 analog S2(M) are not significantly different to the effects of S1.  
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3.2 Structural analysis of LS1, S1(T) and S2(M) using NMR 
3.2.1 Long S1 (LS1) 
 Previously we determined that loss of the four N-terminal amino acids from S2 resulted in a 
loss of concentration dependent structuring and loss of bioactivity [7]. However, addition of SGPY to 
the N-terminus of S1 does not confer S2-like bioactivity (Fig. 2). Therefore, removal of the N-terminal 
tetrapeptide from S2 (short S2 or SS2) results in loss of structure, but addition of the SGPY motif to S1 
may not be sufficient to generate structure. To investigate this we obtained two-dimensional TOCSY 
and NOESY NMR spectra of LS1. From the 2D TOCSY we were able to assign all residues except 
Ser1. When the ROESY spectrum of S1 (Fig. 3A) is compared to that of LS1 (Fig. 3B) it is clear that 
LS1 has far more NOE peaks than S1. The greater number of NOEs in LS1 (Fig. 3B) suggests that the 
addition of four N-terminal amino acids has resulted in the generation of some structure in LS1. 
However, the presence of substantial structure would result in a number of long-range NOE contacts. 
Inspection of the HN-HD region of the overlaid LS1 TOCSY and NOESY spectra shows that there are 
mostly only sequential connections apparent (Fig. 3C). Only one medium range NOE, a dDN(i, i+2), is 
apparent between Leu10 and Phe12, however this may be an ambiguous assignment and will be 
discussed later. Also observed is a d1N(i, i+2) between Ala9 and Leu11 as well as sequential dNN(i, i+1) 
connections between Gly5 and Phe6 and Leu11 and Phe12 (not shown). This suggests that most of the 
apparent structure is located in the C-terminal region. This result is in contrast to S2, in which many 
medium and long range NOEs covering the entire peptide were apparent in the HN-HD region [7]. 
Overall, in the LS1 NOESY spectrum we were able to identify 77 NOEs compared to the more than 
220 NOEs observed in S2 [7]. Thus, the N-terminal tetrapeptide can induce some conformational 
preference, but the structure is not as extensive as observed in S2 and in itself is not sufficient to 
promote S2-like bioactivity.  
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3.2.2 S1(T)  
 S1(T) contains a threonine residue in the penultimate position, as in S2, instead of the 
methionine residue present in S1. Other than the four N-terminal residues, S1 differs from S2 only at 
this position and at position five (S1 numbering) which is a glycine in S2 and an alanine in S1. We 
hypothesised that the threonine for methionine substitution may result in increased potency/efficacy but  
the pharmacological tests showed that bioactivity of S1(T) was not significantly different to S1 (Fig. 2E 
– H). Analysis of the NMR data supports this finding. The ROESY spectrum of S1(T) (Fig. 4A) is 
similar to that of S1 (Fig. 4B). The chemical shifts are all near their „random coil‟ values and there are 
no ROEs present beyond sequential connectivities, indicating that S1(T), like S1, is largely 
unstructured. If the penultimate threonine is indeed important in receptor binding, perhaps by being 
involved in hydrogen-bonding via the side-chain hydroxyl group, then it must require the structuring 
induced by the N-terminal tetrapeptide in S2 in order to be placed in the correct position.          
     
3.2.3 S2(M) 
 If Thr11 is important for S2 bioactivity, then S2(M), which contains the penultimate methionine 
from S1 instead of Thr11, should have reduced bioactivity. The pharmacology results have supported 
this, showing that S2(M) is no more effective than S1 as a muscle relaxant (Fig. 2I-L).  Comparison of 
the HN-HD region of the ROESY spectrum of S2(M) (Fig. 5A) with the same region of S2 (Fig. 5B) 
shows that S2(M) also lacks the array of ROEs indicative of structure that are abundant in S2.  Likely, 
a loss of structure has resulted in the lack of ROEs. Indeed, the number of ROEs in S2(M) is similar to 
LS1 as might be expected given that S2(M) and LS1 differ only by one amino acid at position 9 – 
alanine in LS1 and glycine in S2(M). Closer inspection of the HN-HD region of the overlaid TOCSY 
and ROESY spectra in Fig. 5C shows that S2(M) adopts multiple conformations. All long peptides (S2, 
LS1, S2(M)) that contain Pro3 have cis and trans conformations due to the proline, however S2(M) also 
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has an additional two conformations around Met11. Figure 5C shows that the sequential HN-HD 
connections can follow two divergent paths from Gly9 and consequently Leu10, Met11 and Phe12 have 
two distinct chemical shifts. This suggests that S2(M) can adopt at least four distinct conformations – 
Pro3TransMet11a, Pro3TransMet11b; Pro3CisMet11a and Pro3CisMet11b. Possibly, the splitting of the C-terminal 
residues is a consequence of the cis/trans Pro3 isomerism and could suggest association of the N-
terminal region with the C-terminus either within a folded monomer or possibly in a „head-to-tail‟ 
dimer. However, it is notable that the cis-Proline is a minor component while the signals for the two 
sets of Met11 have similar intensities. If the two conformations of Leu10, Met11 and Phe12 were a result 
of the Pro3 cis/trans isomerisation then it could reasonably be expected that the peak intensities would 
mimic the Pro3 intensities, i.e. one set would have markedly reduced intensity. It is likely then that the 
splitting of Leu10 – Phe12 residues is not related to the cis/trans Pro3 isomerism. The ambiguity in the 
assignment of the dDN(i, i+2) connection between Leu10 and Phe12 in LS1 is because there may also be 
some minor doubling of the Met11 peak in LS1, however any chemical shift difference is minor and the 
TOCSY does not provide sufficient evidence for a second peak. The clear presence of multiple 
conformations in the C-terminal region of S2(M) would undoubtedly impact on the ability of the 
peptide to bind to receptors and induce muscle relaxation. Taken together, the pharmacology and 
structural data indicate that the combination of the four N-terminal residues along with the presence of 
threonine in the penultimate position is necessary to form a peptide with optimal bioactivity. Possibly, 
the side-chain hydroxyl is required for hydrogen bonding with the S2 receptor.  
 
3.3 Structural analysis of LS1 and S2(M) using CD spectroscopy 
 The number of ROEs observed in the ROESY spectra of LS1 and S2(M) (Fig. 3, 5) has 
suggested that both these peptides contain some structure. Previous studies have shown that structure in 
S2 was a consequence of self-association [7], and therefore we now wondered if LS1 and S2(M) also 
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exhibit S2-like concentration-dependent structuring. CD is a useful technique for the determination of 
protein and peptide structure. In the UV region of the CD spectrum the presence of stable structure 
results in optical activity due to the chirality around the amide bond. Initially, we obtained CD spectra 
of LS1 and S2(M) at low concentrations similar to those used in the pharmacology experiments and 
higher concentrations similar to the concentrations used in the NMR experiments (Fig. 6). For LS1 
(Fig. 6A) the CD spectra obtained at both concentrations are very similar. At the lower concentration 
(0.011 mg/mL) the presence of a strong negative peak near 200 nm along with a positive peak at 225 
nm suggests the presence of polyproline-II (PP-II) character [13]. PP-II is a highly extended 
conformation that does not contain backbone hydrogen bonds and is frequently found in „unstructured‟ 
regions of proteins. At a ten-fold higher concentration, the UV CD spectrum of LS1 is similar to that at 
the lower concentration, the negative peak at 200 nm has got stronger (i.e. more negative) but a small 
peak at 225 nm is retained. This suggests that a similar structure is adopted at both concentrations.  
 The CD spectra of S2(M) at high and low concentrations (Fig. 6B) are very different to LS1 
(Fig. 6A) and to S2 [7].  The spectra have a positive peak at 207 nm and negative peaks at 215 nm and 
225 nm. In the higher concentration spectrum the peak at 215 nm that is readily apparent at the lower 
concentration appears as a shoulder on the more intense 225 nm peak.  The S2(M) spectra are quite 
novel and don‟t resemble the spectra that would be obtained from any regular secondary structural 
element nor an unstructured peptide, which would feature a single negative band at a198 nm. 
Furthermore, the lack of similarity to LS1 suggests that S2(M) also does not adopt a PPII conformation. 
Given that the NMR data suggest that S2(M) can adopt at least four different conformations, the CD 
spectrum at the higher concentration is likely a summation of all of these different conformations. The 
fact that the CD spectrum of the lower concentration does not resemble the spectrum of an unstructured 
peptide indicates that, in contrast to S2, S2(M) retains some structure at the concentrations used in the 
pharmacology experiments.    
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 To further investigate the structure of LS1 and S2(M) we undertook temperature dependent 
unfolding experiments. As the temperature is increased from 10qC to 90qC the CD spectra of LS1 
shows a loss of the positive band at 225 nm at both low (Fig. 7A) and high (Fig. 7B) concentrations. 
These data suggest that the PPII structure is lost at higher temperatures; it is notable that even at 90qC, 
and at both concentrations, a negative CD band is observed at 230 nm suggesting some self-
association. As expected, the loss of PPII structure is not cooperative unfolding at either concentration 
(Fig. 7C, D).  The rather unusual CD spectra of S2(M) are very different to those of LS1 -  at the higher 
concentration (Fig. 8A) the negative CD signal at 225 nm remains almost unaffected by raising the 
temperature to 70qC, while there is a significant loss of positive signal at 207 nm. At the lower S2(M) 
concentration (Fig. 8B) the signal loss at 207 nm is more marked, accompanied by a negative band at 
217 nm even at 70qC, which suggests an extended conformation due to self-association.  It is notable 
that at 70qC with both concentrations of S2(M) the spectra do not show evidence for a completely 
unfolded peptide. The thermal denaturation curves (Fig. 8C, D) suggest a sharp transition in structure at 
50qC with a marked loss of the positive CD band at 207 nm. 
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4. Discussion 
 
 The SALMFamide neuropeptides S1 and S2, which share 67% sequence 
identity (Fig. 1), act as muscle relaxants in starfish, but S2 is about ten times more potent than S1. In a 
previous study [7] a structural basis for this difference in the potency of S1 and S2 was investigated, 
focusing on the N-terminal SGPY tetrapeptide that is a feature of the S2 dodecapeptide 
(SGPYSFNSGLTFamide) but not the S1 octapeptide (GFNSALMFamide). It was found that the N-
terminal SGPY motif confers on S2 the property of self-association induced structure at high 
concentrations. Given that S2 structuring is only apparent at high concentrations it is most likely not 
relevant to the physiological roles of S2 as a muscle relaxant in starfish. We note, though, that recent 
studies with bradykinin peptides have shown that conformation can be quite dependent on solution 
composition and it remains possible that other conditions will modify S2‟s oligomerization and 
conformation [14]. We have proposed that the ability of S2 to oligomerize may have implications for 
peptide packing in vesicles prior to release and possibly also for autocrine actions of the peptide 
directly after release when local concentrations are high. Analysis of the bioactivity of an N-terminally 
truncated form of S2 (SS2; SFNSGLTFamide), which like S1 does not exhibit self-association induced 
structure, yielded ambiguous findings - the bioactivity of SS2 was found to be either inferior or 
superior to that of S2, depending on the dose and muscle preparation tested. Thus, the contribution of 
the N-terminal SGPY sequence to the bioactivity of S2 remains unclear. Here we have further 
investigated this issue by analysis of the bioactivity and structural properties of chimeric analogs of S1 
and S2. 
 Long S1 or LS1 (SGPYGFNSALMFamide), a chimeric peptide comprising the N-terminal 
tetrapeptide of S2 and the C-terminal octapeptide of S1, was tested and analysed to investigate if 
addition of the N-terminal SGPY sequence would confer S2-like bioactivity and structure on S1. It was 
found that the bioactivity of LS1 as a muscle relaxant was not significantly different to that of S1 and 
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that LS1 does not exhibit self-association induced structure.  However, some structuring was detected 
in the C-terminal region of LS1 and the presence of a positive peak at 225 nm in CD spectra suggests 
the presence of a polyproline-II-type conformation. Thus, addition of the N-terminal SGPY motif does 
confer some structure on S1, but it is not equivalent to that seen with S2 and does not appear to 
enhance bioactivity. Collectively, these findings indicate that the superior bioactivity of S2 in 
comparison with S1 is not largely attributable to the presence of the N-terminal SGPY motif in S2. 
Therefore, we investigated the contribution of residues that differ in the C-terminal region of S1 and 
S2. 
 The bioactivity of S1(T), an analog of S1 with a threonine residue replacing the methionine 
residue that is penultimate to the C-terminal amide in S1, was found not to be significantly different to 
that of S1. Furthermore, like S1 [7], the S1(T) octapeptide did not exhibit a stable structure in solution. 
Thus, conversion of the C-terminal region of S1 (LMFamide) to an S2-type C-terminal sequence 
(LTFamide) is not sufficient on its own to confer S2-like bioactivity on S1. However, conversion of the 
C-terminal region of S2 (LTFamide) to an S1-type C-terminal sequence (LMFamide) results in loss of 
S2-type bioactivity – thus, the relaxing effects of the S2 analog S2(M) are significantly less than the 
effects of S2 and not significantly different to the effects of S1. Interestingly, this amino acid 
conversion also results in loss of the self-associating property of S2 to form a stable conformation at 
high concentrations. However, like the LS1 peptide, S2(M) does exhibit some structuring but it lacks 
the stability seen with S2 at high concentrations and appears to adopt multiple conformations.  
 Collectively, the findings of our previous study [7] and the findings from the experiments 
reported here indicate that the superior bioactivity of S2 compared to S1 is largely attributable to 
differences in the C-terminal region of these peptides. In particular, the loss of bioactivity seen in the 
S2 analog S2(M) indicates that the C-terminal LTFamide motif of S2 appears to be a key determinant 
of its superior bioactivity in comparison with S1. This presumably reflects differences in the properties 
of threonine and methionine and hence how they may interact with residues that form receptor binding 
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sites for S2 - perhaps the side-chain hydroxyl group in the threonine residue is required for formation 
of hydrogen bonds. The presence of multiple conformations around Met11 in S2(M) suggests that, in 
addition to Thr11 potentially supporting interactions with the S2 receptor, it is also possible that this 
residue supports intra- or inter-molecular hydrogen-bonding. However, the contribution of the N-
terminal SGPY sequence to the bioactivity of S2 should not be dismissed. The reduced bioactivity of 
the N-terminally truncated form of S2 (SS2) seen in some preparations [7] indicates that the SGPY 
motif contributes to S2‟s bioactivity. The SGPY motif clearly confers varying degrees of structural 
stability on the dodecapeptides S2, LS1 and S2(M) and we propose that it is this property in 
combination with the C-terminal residues of S2 that accounts for S2‟s superior bioactivity in 
comparison with S1.  Further understanding of S2‟s bioactivity might be achieved if we could solve the 
structure of the high-concentration multimeric structure. However, solving the structure of monomeric 
S2 based on our NOESY data is very difficult because at NMR concentrations S2 is multimeric and 
lowering the concentration results in loss of structure. Under NMR conditions deconvoluting our NOE 
data to determine intra-monomer from inter-monomer contacts is not possible, especially for a peptide 
of only 12 amino-acids. Furthermore, it is difficult to assess how the multimeric structure has 
influenced NOE intensities and thus conversion of peak intensity to distant restraints is likely to result 
in incorrect distances. For example, a „head-to-head‟ dimer could result in NOE contacts for the same 
proton pair that is a mixture of both intra- and inter-residue contacts. Diffusion Ordered Spectroscopy 
of S2 was undertaken to try to elucidate the arrangement of the oligomeric structure (data not shown), 
but given the small size of the peptide it is very difficult to deconvolute the diffusion coefficient to 
differentiate an unfolded monomer from a folded dimer, trimer or tetramer.  
 In conclusion, our analysis of chimeric SALMFamide neuropeptides has revealed how 
neuropeptide bioactivity is determined by a complex interplay of sequence and conformation. Further 
insights into the structural basis of the differences in the potency of S1 and S2 as muscle relaxants in 
starfish could be obtained if the receptor(s) that mediate the effects of these peptides is/are identified. 
 20 
Based on sequence similarities that SALMFamide-type neuropeptides share with neuropeptides that 
have been identified in other phyla, candidate G-protein coupled receptors for SALMFamides have 
been proposed (e.g. GnIH/NPFF-type and QRFP-type receptors; [1, 15]). However, definitive insights 
will require cloning, heterologous expression and pharmacological characterisation of candidate 
receptors. 
 Another fascinating avenue for future research will be to extend our analysis of the bioactivity 
and structural properties of S1, S2 and their chimeric analogs to other SALMFamide-type 
neuropeptides that have been discovered in starfish and in other echinoderms. Analysis of the genome 
sequence of the starfish Patiria miniata has revealed that S1 is derived from a precursor protein that 
contains six other L-type SALMFamides. On the other hand, the S2-like neuropeptide in P. miniata 
(SNGPYSMSGLRSLTFamide) is derived from a different precursor protein, which also comprises 
eight F-type or F-type-like SALMFamides [16]. Recently, sequencing of the neural transcriptome of A. 
rubens has enabled identification of corresponding precursors in this species, with S1 derived from a 
precursor comprising six L-type SALMFamides and S2 derived from a precursor comprising seven F-
type or F-type-like SALMFamides (D.C. Semmens & M.R. Elphick, unpublished data). 
Immunocytochemical localisation of S1 and S2 in A. rubens has revealed that these two peptides, and 
hence their precursor-associated peptides, are expressed in different populations of neurons [6, 17]. 
Therefore, we can collectively infer from these observations that S1 is released from neurons as one 
constituent of a “cocktail” of seven L-type SALMFamides. On the other hand, it appears that S2 is 
released by a different population of neurons as one constituent of a “cocktail” of eight SALMFamides, 
with the seven other peptides being F-type or F-type-like SALMFamides. Therefore, in comparing the 
bioactivity and structural properties of S1 and S2, as reported previously [7] and here, we are in fact 
comparing two L-type SALMFamides that are derived from different precursors and different 
populations of neurons. Furthermore, because both S1 and S2 are derived from precursor proteins that 
contain other SALMFamides, testing and comparing the effects of S1 and S2 in vitro is not 
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representative of a physiological scenario. In future studies it will be of interest to compare the 
structural and functional properties of S1 with other L-type SALMFamides that are derived from the S1 
precursor. Furthermore, analysis of the in vitro actions of a “cocktail” of the SALMFamides that are 
derived from the S1 precursor will reveal pharmacological actions that are representative of 
physiological processes in vivo. Similarly, it will be interesting to compare the effects of S2 with the 
effects of F-type and F-type-like SALMFamides that are derived from the S2 precursor and to compare 
the effects of peptides tested individually with the effects of the entire “cocktail” of SALMFamides that 
are derived from the S2 precursor. Combined with comparative analysis of the structural properties of 
all fifteen SALMFamides that are derived from the S1 and S2 precursors, it may then be possible to 
gain insights into the evolutionary and functional significance of the heterogeneous mixtures of 
SALMFamides that occur in starfish and in other echinoderms.  
 Our work on SALMFamides has broad relevance because the occurrence of multiple related 
neuropeptides derived from a single precursor protein is a common phenomenon, particularly in 
invertebrates [18]. However, the functional significance of these neuropeptide “cocktails” is not 
understood [19]. As an example, in the nematode C. elegans, a single precursor protein generates eight 
similar peptides belonging to the FMRFamide family of neuropeptides.  Deletion of this gene results in 
five distinct and different behavioural defects but it is not clear how individual peptides contribute to a 
specific phenotype [20]. Similar to our findings in this work, it appears that conformation preferences 
of individual FMRFamide-type neuropeptides in molluscs play a role in modulating receptor binding. It 
is suggested that only a single conformation will bind to the receptor and therefore the effective 
neuropeptide concentration is less than the expressed concentration [21]. Thus, an understanding of the 
interplay of sequence, conformation and intra- and inter-peptide interactions may be the key to 
elucidation of the functional significance of neuropeptide “cocktails”. 
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Figure Legends 
 
Figure 1. Comparison of the sequences of S1, S2,  SS2 (short S2), LS1 (long S1), S1(T) and S2(M). 
Residues that are identical in all six peptides are shown in black and residues that are variable or are 
not present in some peptides are shown in red. 
 
Figure 2. Analysis of pharmacological effects of LS1, S1(T) and S2(M) on cardiac stomach and tube 
foot preparations. A. LS1 causes dose-dependent relaxation of cardiac stomach preparations. However, 
although the effect 1 µM LS1 is significantly greater than 0.1 µM LS1 (p = 0.02; t-test), the effect of 1 
µM LS1 is not significantly different to the effect of 10 µM LS1 (p = 0.74; t-test). B. When tested at 1 
µM, LS1 is significantly less effective than S2 (p = 4.65E-06; ***; t-test) but is not significantly 
different to S1 (p = 0.138; t-test) as a relaxant of cardiac stomach preparations. C. LS1 causes dose-
dependent relaxation of tube foot preparations. D. When tested at 1 µM, LS1 is significantly less 
effective than S2 (p = 9.04E-10; ***; t-test) but is not significantly different to S1 (p = 0.14; t-test) as a 
relaxant of tube foot preparations. E. S1(T) causes dose-dependent relaxation of cardiac stomach 
preparations. F. When tested at 1 µM, S1(T) is significantly less effective than S2 (p = 0.0055; ***; t-
test) but is not significantly different to S1 (p = 0.4; t-test) as a relaxant of cardiac stomach 
preparations. G. S1(T) causes dose-dependent relaxation of tube foot preparations. H. When tested at 1 
µM, S1(T) is significantly less effective than S2 (p = 7.856 E-11; ***; t-test) but is not significantly 
different to S1 (p = 0.129; t-test) as a relaxant of the tube foot preparations. I. S2(M) causes dose-
dependent relaxation of cardiac stomach preparations. J. When tested at 1 µM, S2(M) is significantly 
less effective than S2 (p = 1.648E8; ***; t-test) but is not significantly different to S1 (p = 0.012; t-test) 
as a relaxant of cardiac stomach preparations K. S2(M) causes dose-dependent relaxation of tube foot 
preparations. L. When tested at 1 µM, S2(M) is significantly less effective than S2 (p = 8.999E-12; 
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***; t-test) but is not significantly different to S1 (p = 0.241; t-test) as a relaxant of the tube foot 
preparations. 
 
Figure 3.  Analysis by NMR (600 MHz) suggests LS1 contains some structure. The amide region of the 
ROESY spectrum (Wm = 300 ms) of S1 (A) shows no non-sequential cross-peaks which correlates with 
the lack of structure in this peptide. In contrast, the NOESY spectrum (Wm = 300 ms) of LS1 (B)  (2mM, 
pH 5.6, 303K) shows non-sequential cross-peaks, especially to the side-chains of Phe6/Phe12 between 
7.0 and 7.5 ppm, suggesting that LS1 contains some structure. Overlay of the NH-HD region of the LS1 
ROESY spectrum (red) and the TOCSY spectrum (Wm= 65 ms, blue) shows the sequential connections 
(solid lines) along with a possible dDN(i, i+2) connection between L10 and F12 (dotted line). 
 
Figure 4. S1T is not structured. The HN-HD region of 600 MHz ROESY spectrum (Wm = 300 ms) of 
S1(T) (2 mM, pH 5.6, 283K) (A) shows only sequential connectivities similarly to S1 (B) and both 
have a lack of medium and long range contacts that would indicate structure. The box labelled G1 
represents the intraresidue HN-HD peak of G1 observed in the TOCSY but not in the ROESY. 
 
Figure 5. S2(M) contains multiple conformations. The amide region of the 600 MHz NOESY spectrum 
(Wm = 300 ms) of S2(M) (2 mM, pH 5.4, 283K) (A) compared to the same region of the NOESY 
spectrum of S2 (B)  (C) Overlay of the NH-HD region of the S2(M) NOESY spectrum (red) and 
TOCSY spectrum (blue) shows sequential connections (solid lines). The dashed line highlights a 
second set of sequential connections from Leu10 to Phe12 that suggests the presence of an alternative 
conformation. 
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Figure 6. CD of LS1 and S2(M) at high and low concentrations. Panel A shows the CD spectra of LS1 
at low (0.011 mg/mL, black trace) and high (0.13 mg/mL, red trace) concentrations. The positive peak 
at 225 nm, particularly at low concentration, suggests the presence of polyproline II conformation. The 
CD spectra of S2(M) (Panel B) at low (0.012 mg/mL, black trace) and high (0.18 mg/mL red trace) are 
quite unusual and not typical of regular secondary structure. The presence of the positive band at 207 
nm and the negative band at 225 nm in both spectra suggests that the peptide has some similarity at 
both concentrations.      
 
Figure 7. Thermal melting CD spectra of LS1. Panel A shows the CD spectra of LS1 (0.13 mg/mL) 
obtained as the temperature is raised from 10qC (black trace) to 90qC (purple trace) in 5qC increments. 
Panel B shows the CD spectra of LS1 (0.011 mg/mL) obtained as the temperature is raised from 10qC 
(black trace) to 90qC (purple trace). In both cases a spectrum was obtained at 10qC after cooling from 
90qC and the unfolding was reversible. In neither high (Panel A) nor low concentration (Panel B) 
spectra is there evidence of a completely unfolded peptide, even at 90qC. Panels C and D show the 
ellipticity at 223 nm plotted as a function of temperature, and in neither case is there evidence of 
cooperative unfolding.    
 
Figure 8. Thermal melting CD spectra of S2(M). Panel A shows the CD spectra of S2(M) (0.18 
mg/mL) obtained as the temperature is raised from 10qC (black trace) to 70qC (blue trace) in 5qC 
increments. Panel B shows the CD spectra of S2(M) (0.012 mg/mL) obtained as the temperature is 
raised from 10qC (black trace) to 70qC (purple trace). In neither high (Panel A) nor low concentration 
(Panel B) spectra is there evidence of a completely unfolded peptide at the highest temperature tested. 
Panels C and D show the ellipticity at 207 nm, 217 nm and 225 nm plotted as a function of 
temperature. 
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